| Name | Title | Contact Details |
|---|---|---|
William Blake |
Chief Technology Officer | Profile |
Genmab is a leading international biotechnology company that aims to improve the lives of patients by creating and developing innovative antibody products. The company was founded in Copenhagen, Denmark in 1999. Genmab`s ordinary shares are publicly traded on Nasdaq Copenhagen and American Depositary Shares under its ADR Program are listed in the United States on the Nasdaq Global Select Market. Genmab is developing a pipeline of antibody therapeutics with eighteen products in clinical development, including two marketed products, DARZALEX® (daratumumab) and Arzerra® (ofatumumab), and approximately 20 in-house and partnered pre-clinical programs. Our pipeline currently includes naked antibodies, Antibody Drug Conjugates (ADCs), bispecific antibodies created from our DuoBody® technology platform, and antibodies created with our HexaBody® technology.
Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.
Speedball Fitness is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
EdiGENE Corporation is an emerging biotech company focusing on developing transformative therapeutics for unmet medical needs using its proprietary technologies on CRISPR and protein engineering platforms. The company has a strong foundation on intellectual property licensed from the University of Tokyo.
Odyssey Research Services is a Bismarck, ND-based company in the Healthcare, Pharmaceuticals, and Biotech sector.